Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry

Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) and its ligand PD-L1 have proven to be efficient cancer therapies in a subset of patients. From all the patients with various cancer types, only 20% have a positive response. Being able to distinguish patients that do express...

Descripción completa

Detalles Bibliográficos
Autores principales: Chigoho, Dora Mugoli, Lecocq, Quentin, Awad, Robin Maximilian, Breckpot, Karine, Devoogdt, Nick, Keyaerts, Marleen, Caveliers, Vicky, Xavier, Catarina, Bridoux, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228271/
https://www.ncbi.nlm.nih.gov/pubmed/34201323
http://dx.doi.org/10.3390/ph14060550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228271/
https://www.ncbi.nlm.nih.gov/pubmed/34201323
http://dx.doi.org/10.3390/ph14060550

Ejemplares similares